首页 > 最新文献

Journal of Thrombosis and Haemostasis最新文献

英文 中文
Molecular basis of platelet granule defects 血小板颗粒缺陷的分子基础。
IF 5.5 2区 医学 Q1 HEMATOLOGY Pub Date : 2025-02-01 DOI: 10.1016/j.jtha.2024.11.016
Helen H.Y. Yao , Walter H.A. Kahr
Platelets are small, discoid, anucleate blood cells that play key roles in clotting and other functions involved in health and disease. Platelets are derived from bone marrow-resident megakaryocytes, which undergo a complex developmental process where they increase dramatically in size and produce an abundance of organelles destined for platelets. These organelles include mitochondria, lysosomes, peroxisomes, and 2 unique types of secretory organelles: α- and dense (δ-) granules. δ-Granules contain small molecules, including adenosine triphosphate, adenosine diphosphate, serotonin, and ions, such as calcium and zinc (Ca2+ and Zn2+). α-Granules contain a variety of cargo proteins, which, when secreted by activated platelets, are involved in processes such as hemostasis (eg, fibrinogen and von Willebrand factor), angiogenesis, inflammation, and wound healing. Investigations of patients with inherited conditions resulting in decreased/abnormal platelet secretory granules have led to the identification of proteins, protein complexes, and cellular processes involved in their production by megakaryocytes. Notably, studies of ARPC1B deficiency, Hermansky–Pudlak, and Chediak–Higashi syndromes have linked several genes/proteins to δ-granule biogenesis. Studies of multisystemic arthrogryposis, renal dysfunction, and cholestasis syndrome revealed the requirement of 2 proteins, VPS33B and VPS16B, in α-granule formation. Identification of the genetic cause of gray platelet syndrome established that NBEAL2 is an additional protein needed for α-granule cargo retention. These discoveries enabled studies using animal models, cell culture, and molecular analysis to gain insights into the roles of proteins and cellular processes involved in platelet secretory granule production, which are discussed in this review.
血小板是一种小的、盘状的无核血细胞,在凝血和其他与健康和疾病有关的功能中起着关键作用。血小板来源于骨髓巨核细胞,巨核细胞经历了一个复杂的发育过程,在这个过程中,它们的大小急剧增加,并产生大量用于血小板的细胞器。这些细胞器包括线粒体、溶酶体、过氧化物酶体和两种独特类型的分泌细胞器:α和致密(δ)颗粒。致密的颗粒含有小分子,包括ATP、ADP和血清素,以及离子,如Ca2+和Zn2+。α-颗粒含有多种载货蛋白,这些蛋白由活化的血小板分泌,参与止血(如纤维蛋白原和血管性血友病因子)、血管生成、炎症和伤口愈合等过程。对导致血小板分泌颗粒减少/异常的遗传性疾病患者的研究导致了巨核细胞产生的蛋白质、蛋白质复合物和细胞过程的鉴定。值得注意的是,ARPC1B缺乏症、Hermansky-Pudlak和Chediak-Higashi综合征的研究已经将几个基因/蛋白质与致密颗粒生物发生联系起来。多系统ARC综合征的研究表明,α-颗粒形成需要VPS33B和VPS16B两种蛋白。灰色血小板综合征的遗传原因鉴定表明,NBEAL2是α-颗粒货物保留所需的额外蛋白质。这些发现使得利用动物模型、细胞培养和分子分析的研究能够深入了解血小板分泌颗粒产生过程中蛋白质和细胞过程的作用,本文将对此进行讨论。
{"title":"Molecular basis of platelet granule defects","authors":"Helen H.Y. Yao ,&nbsp;Walter H.A. Kahr","doi":"10.1016/j.jtha.2024.11.016","DOIUrl":"10.1016/j.jtha.2024.11.016","url":null,"abstract":"<div><div>Platelets are small, discoid, anucleate blood cells that play key roles in clotting and other functions involved in health and disease. Platelets are derived from bone marrow-resident megakaryocytes, which undergo a complex developmental process where they increase dramatically in size and produce an abundance of organelles destined for platelets. These organelles include mitochondria, lysosomes, peroxisomes, and 2 unique types of secretory organelles: α- and dense (δ-) granules. δ-Granules contain small molecules, including adenosine triphosphate, adenosine diphosphate, serotonin, and ions, such as calcium and zinc (Ca<sup>2+</sup> and Zn<sup>2+</sup>). α-Granules contain a variety of cargo proteins, which, when secreted by activated platelets, are involved in processes such as hemostasis (eg, fibrinogen and von Willebrand factor), angiogenesis, inflammation, and wound healing. Investigations of patients with inherited conditions resulting in decreased/abnormal platelet secretory granules have led to the identification of proteins, protein complexes, and cellular processes involved in their production by megakaryocytes. Notably, studies of ARPC1B deficiency, Hermansky–Pudlak, and Chediak–Higashi syndromes have linked several genes/proteins to δ-granule biogenesis. Studies of multisystemic arthrogryposis, renal dysfunction, and cholestasis syndrome revealed the requirement of 2 proteins, VPS33B and VPS16B, in α-granule formation. Identification of the genetic cause of gray platelet syndrome established that NBEAL2 is an additional protein needed for α-granule cargo retention. These discoveries enabled studies using animal models, cell culture, and molecular analysis to gain insights into the roles of proteins and cellular processes involved in platelet secretory granule production, which are discussed in this review.</div></div>","PeriodicalId":17326,"journal":{"name":"Journal of Thrombosis and Haemostasis","volume":"23 2","pages":"Pages 381-393"},"PeriodicalIF":5.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142770203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Integrative phosphoproteomic analyses reveal hemostatic-endothelial signaling interplay 综合磷酸蛋白组分析揭示了止血-内皮信号的相互作用。
IF 5.5 2区 医学 Q1 HEMATOLOGY Pub Date : 2025-02-01 DOI: 10.1016/j.jtha.2024.10.011
Stijn A. Groten , Bart L. van den Eshof , Floris P.J. van Alphen , Alexander B. Meijer , Maartje van den Biggelaar , Arie J. Hoogendijk

Background

The vascular endothelial cell (EC) monolayer plays a crucial part in maintaining hemostasis. An extensive array of G protein-coupled receptors allows ECs to dynamically act on key hemostatic stimuli such as thrombin and histamine. The impact of these individual stimuli on EC signal transduction has been the subject of various studies, but insight into discordant and concordant EC signaling between different G protein-coupled receptors remains limited.

Objectives

To elucidate histamine and protease-activated receptor (PAR1-4) signaling cascades in ECs, discern overlapping and diverging regulation between these stimuli and their effect on the EC monolayer.

Methods

We employed stable isotope labeling by amino acids in cell culture mass spectrometry-based phosphoproteomics on in vitro cultured blood outgrowth ECs stimulated with histamine and different PAR1 to 4 peptides. We investigated key phosphosites through immuno(fluorescence) staining and determined effects on barrier function through transendothelial resistance assays.

Results

EC histamine activation initiated an extensive (kinase) signaling network (including MAPK3, STAT3, and CTNND1). PAR1 and PAR2 receptors induced highly similar signaling cascades, whereas PAR3 and PAR4 induced minimal phospho-regulation. Integration of all applied stimuli indicated uniquely activated proteins between both stimuli, as well as a general overlapping activation of cell junction and actin cytoskeletal proteins.

Conclusion

We provide an integrative phosphoproteomic analysis of histamine and PAR agonists in the endothelium that highlights the endothelial response programs that are at the basis of regulating hemostasis.
背景:血管内皮细胞(EC)单层在维持止血方面发挥着至关重要的作用。一系列广泛的 G 蛋白偶联受体(GPCR)使血管内皮细胞能够动态地作用于凝血酶和组胺等关键止血刺激。这些刺激对心血管细胞信号传导的影响一直是各种研究的主题,但对不同 GPCR 之间不和谐和和谐的心血管细胞信号传导的了解仍然有限:目的:阐明组胺和蛋白酶激活受体(PAR1-4)在内皮细胞中的信号级联,辨别这些刺激之间的重叠和分歧调控及其对内皮细胞单层的影响:方法:我们采用基于氨基酸稳定同位素标记的细胞培养(SILAC)质谱技术,对组胺和不同蛋白酶激活受体肽(PAR1-4)刺激下体外培养的 BOECs 进行磷酸化蛋白质组学研究。我们通过免疫(荧光)染色研究了关键磷酸位点,并通过跨内皮阻力测定确定了对屏障功能的影响:结果:EC组胺激活启动了一个广泛的(激酶)信号网络(其中包括MAPK3、STAT3和CTNND1)。PAR1 和 PAR2 受体诱导了高度相似的信号级联,而 PAR3 和 PAR4 则诱导了最小的磷酸化调节。对所有应用刺激的整合表明,两种刺激都有独特的激活蛋白,细胞连接蛋白和肌动蛋白的激活也普遍重叠:我们对组胺和 PAR 激动剂在内皮中的作用进行了综合磷酸蛋白组学分析,突出了内皮反应程序是调节止血的基础。
{"title":"Integrative phosphoproteomic analyses reveal hemostatic-endothelial signaling interplay","authors":"Stijn A. Groten ,&nbsp;Bart L. van den Eshof ,&nbsp;Floris P.J. van Alphen ,&nbsp;Alexander B. Meijer ,&nbsp;Maartje van den Biggelaar ,&nbsp;Arie J. Hoogendijk","doi":"10.1016/j.jtha.2024.10.011","DOIUrl":"10.1016/j.jtha.2024.10.011","url":null,"abstract":"<div><h3>Background</h3><div>The vascular endothelial cell (EC) monolayer plays a crucial part in maintaining hemostasis. An extensive array of G protein-coupled receptors allows ECs to dynamically act on key hemostatic stimuli such as thrombin and histamine. The impact of these individual stimuli on EC signal transduction has been the subject of various studies, but insight into discordant and concordant EC signaling between different G protein-coupled receptors remains limited.</div></div><div><h3>Objectives</h3><div>To elucidate histamine and protease-activated receptor (PAR1-4) signaling cascades in ECs, discern overlapping and diverging regulation between these stimuli and their effect on the EC monolayer.</div></div><div><h3>Methods</h3><div>We employed stable isotope labeling by amino acids in cell culture mass spectrometry-based phosphoproteomics on <em>in vitro</em> cultured blood outgrowth ECs stimulated with histamine and different PAR1 to 4 peptides. We investigated key phosphosites through immuno(fluorescence) staining and determined effects on barrier function through transendothelial resistance assays.</div></div><div><h3>Results</h3><div>EC histamine activation initiated an extensive (kinase) signaling network (including MAPK3, STAT3, and CTNND1). PAR1 and PAR2 receptors induced highly similar signaling cascades, whereas PAR3 and PAR4 induced minimal phospho-regulation. Integration of all applied stimuli indicated uniquely activated proteins between both stimuli, as well as a general overlapping activation of cell junction and actin cytoskeletal proteins.</div></div><div><h3>Conclusion</h3><div>We provide an integrative phosphoproteomic analysis of histamine and PAR agonists in the endothelium that highlights the endothelial response programs that are at the basis of regulating hemostasis.</div></div>","PeriodicalId":17326,"journal":{"name":"Journal of Thrombosis and Haemostasis","volume":"23 2","pages":"Pages 717-730"},"PeriodicalIF":5.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142502856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intensive FVIII replacement in hemophilia patients with hypertrophic synovium: a randomized study 肥厚性滑膜血友病患者的强化 FVIII 替代治疗:随机研究。
IF 5.5 2区 医学 Q1 HEMATOLOGY Pub Date : 2025-02-01 DOI: 10.1016/j.jtha.2024.10.018
Matteo Nicola Dario Di Minno , Ilenia Lorenza Calcaterra , Erminia Baldacci , Renato Marino , Federica Valeri , Rita Carlotta Santoro , Gianluigi Pasta , Carlo Martinoli , Italian Association of Haemophilia Centers Musculoskeletal Working Group

Background

Hypertrophic synovium (HS) is a marker of disease activity in persons with hemophilia (PwH). Although some recommendations suggest intensifying prophylaxis in PwH with HS, no validated schedules are available.

Objectives

We explored the efficacy of intensive factor VIII (FVIII) replacement treatment in PwH with HS.

Methods

In a randomized, open-label study, PwH with HS were randomized to receive pharmacokinetics-driven prophylaxis targeting a FVIII trough level of 8% to 12% (intensive treatment arm [ITA]) or 3% to 5% (standard treatment arm [STA]). The primary outcome was HS reduction/resolution in the 2 treatment arms.

Results

A total of 39 PwH were randomized to ITA and 36 to STA. During the study, we found a lower annual bleeding rate and a higher rate of annual bleeding rate zero in the ITA than in the STA. HS reduction/resolution was reported in 35.9% of cases in the ITA and 8.4% in the STA. In detail, in the ITA ,10.3% achieved HS reduction and 25.6% complete HS resolution, as compared to 5.6% and 2.8% in the STA. Cox regression showed that ITA was associated with HS reduction/resolution (hazard ratio: 4.75; 95% CI: 1.36-16.57; P = .014) and HS complete resolution (hazard ratio: 10.79; 95% CI: 1.38-84.45; P = .023). The analysis of the 127 joints with HS (54 elbows, 41 knees, and 32 ankles) consistently confirmed similar results.

Conclusion

In this randomized study, we found a ∼5-fold higher rate of HS reduction/resolution and a ∼10-fold higher rate of HS resolution in the ITA than in the STA.
背景和目的:肥厚性滑膜(HS)是血友病患者(PwH)疾病活动的标志。尽管一些建议提出要加强对血友病患者的预防,但目前尚无有效的时间表。我们探讨了强化因子 VIII(FVIII)替代治疗对血友病患者的疗效:在一项随机、开放标签研究中,患有 HS 的 PwH 被随机分配接受药代动力学驱动的预防治疗,目标是 FVIII 通过水平达到 8%-12%(强化治疗组 [ITA])或 3%-5%(标准治疗组 [STA])。两个治疗组的主要结果是HS减少/缓解:共有 39 名患者被随机分配到 ITA 治疗组,36 名患者被随机分配到 STA 治疗组。在研究过程中,我们发现与 STA 相比,ITA 的年出血率(ABR)更低,且 ABR 零发生率更高。据报告,35.9%的病例(ITA)和 8.4% 的病例(STA)HS 减少/消退。具体而言,在 ITA 中,10.3% 的病例实现了 HS 减少,25.6% 的病例完全消除了 HS,而在 STA 中,这一比例分别为 5.6% 和 2.8%。COX回归显示,ITA与HS缩小/消退(危险比[HR]:4.75,95%置信区间[CI]:1.36-16.57,P=0.014)和HS完全消退(HR:10.79,95%置信区间[CI]:1.38-84.45,P=0.023)相关。对127个患有HS的关节(54个肘关节、41个膝关节和32个踝关节)的分析也证实了类似的结果:在这项随机研究中,我们发现与STA相比,ITA的HS减少/缓解率高5倍,HS缓解率高10倍。
{"title":"Intensive FVIII replacement in hemophilia patients with hypertrophic synovium: a randomized study","authors":"Matteo Nicola Dario Di Minno ,&nbsp;Ilenia Lorenza Calcaterra ,&nbsp;Erminia Baldacci ,&nbsp;Renato Marino ,&nbsp;Federica Valeri ,&nbsp;Rita Carlotta Santoro ,&nbsp;Gianluigi Pasta ,&nbsp;Carlo Martinoli ,&nbsp;Italian Association of Haemophilia Centers Musculoskeletal Working Group","doi":"10.1016/j.jtha.2024.10.018","DOIUrl":"10.1016/j.jtha.2024.10.018","url":null,"abstract":"<div><h3>Background</h3><div>Hypertrophic synovium (HS) is a marker of disease activity in persons with hemophilia (PwH). Although some recommendations suggest intensifying prophylaxis in PwH with HS, no validated schedules are available.</div></div><div><h3>Objectives</h3><div>We explored the efficacy of intensive factor VIII (FVIII) replacement treatment in PwH with HS.</div></div><div><h3>Methods</h3><div>In a randomized, open-label study, PwH with HS were randomized to receive pharmacokinetics-driven prophylaxis targeting a FVIII trough level of 8% to 12% (intensive treatment arm [ITA]) or 3% to 5% (standard treatment arm [STA]). The primary outcome was HS reduction/resolution in the 2 treatment arms.</div></div><div><h3>Results</h3><div>A total of 39 PwH were randomized to ITA and 36 to STA. During the study, we found a lower annual bleeding rate and a higher rate of annual bleeding rate zero in the ITA than in the STA. HS reduction/resolution was reported in 35.9% of cases in the ITA and 8.4% in the STA. In detail, in the ITA ,10.3% achieved HS reduction and 25.6% complete HS resolution, as compared to 5.6% and 2.8% in the STA. Cox regression showed that ITA was associated with HS reduction/resolution (hazard ratio: 4.75; 95% CI: 1.36-16.57; <em>P</em> = .014) and HS complete resolution (hazard ratio: 10.79; 95% CI: 1.38-84.45; <em>P</em> = .023). The analysis of the 127 joints with HS (54 elbows, 41 knees, and 32 ankles) consistently confirmed similar results.</div></div><div><h3>Conclusion</h3><div>In this randomized study, we found a ∼5-fold higher rate of HS reduction/resolution and a ∼10-fold higher rate of HS resolution in the ITA than in the STA.</div></div>","PeriodicalId":17326,"journal":{"name":"Journal of Thrombosis and Haemostasis","volume":"23 2","pages":"Pages 458-465"},"PeriodicalIF":5.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142546157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Biophysical characterization of blood coagulation factor VIII binding to lipid nanodiscs that mimic activated platelet surfaces 血液凝固因子 VIII 与模拟活化血小板表面的脂质纳米圆片结合的生物物理特征。
IF 5.5 2区 医学 Q1 HEMATOLOGY Pub Date : 2025-02-01 DOI: 10.1016/j.jtha.2024.11.003
Nathan G. Avery, Isabelle R. Young, Selena Lu, Jordan D. Vaughan, Patrick S. Korus, Tera N. Richardson, Kenneth C. Childers, Serge L. Smirnov, P. Clint Spiegel Jr.

Background

Following proteolytic activation, activated blood coagulation factor (F)VIII (FVIIIa) binds to activated platelet membranes, forming the intrinsic tenase complex with activated FIX (FIXa). Previous studies have identified the C1 and C2 domains as the membrane binding domains of FVIII through conserved arginine residues. A membrane binding model for the FVIII C domains proposes that surface-exposed hydrophobic and positively charged residues at each C domain interact with the membrane, yet a comprehensive thermodynamic and structural description of this interaction is lacking.

Objectives

To determine residues of interaction, thermodynamics, and membrane binding preference for FVIII membrane association.

Methods

The binding of FVIII constructs to lipid nanodiscs was characterized by nuclear magnetic resonance, isothermal titration calorimetry, bio-layer interferometry, and X-ray crystallography.

Results

The thermodynamics of FVIII membrane binding indicated that the C1 domain associates through an enthalpically driven process while the C2 domain is entropically driven. Alanine mutations to surface-exposed hydrophobic residues in the C2 domain revealed differential effects on membrane binding, highlighting important determinants at the residue level. The structure of a C2 double mutant, L2251A/L2252A, demonstrated that its decreased affinity is likely due to decreasing the surface area hydrophobicity. Nuclear magnetic resonance studies with the C2 domain identified residues of interaction with soluble O-phospho-L-serine as well as lipid nanodiscs. Lastly, increasing phosphatidylethanolamine and decreasing phosphatidylserine content decreased overall FVIII affinity for membrane surfaces.

Conclusion

This study provides further insight into the molecular basis for how FVIII interacts with platelets to form the intrinsic tenase complex.
背景:蛋白水解活化后,活化的凝血因子 VIII(FVIIIa)与活化的血小板膜结合,与活化的因子 IX(FIXa)形成内在十酶复合物。先前的研究通过保守的精氨酸残基确定了 C1 和 C2 结构域为 FVIII 的膜结合结构域。FVIII C 结构域的膜结合模型提出,每个 C 结构域中表面暴露的疏水和带正电荷的残基与膜相互作用,但缺乏对这种相互作用的全面热力学和结构描述:确定 FVIII 与膜结合的相互作用残基、热力学和膜结合偏好:方法:利用核磁共振(NMR)、等温滴定量热法(ITC)、生物层干涉测量法(BLI)和 X 射线晶体学对 FVIII 构建物与脂质纳米盘的结合进行表征:FVIII膜结合的热力学表明,C1结构域是通过焓驱动过程结合的,而C2结构域则是由熵驱动的。对 C2 结构域中暴露于表面的疏水残基进行丙氨酸突变显示了对膜结合的不同影响,突出了残基水平上的重要决定因素。C2 双突变体 L2251A/L2252A 的结构表明,其亲和力下降可能是由于表面疏水性降低所致。对 C2 结构域的核磁共振研究发现了与可溶性 O-磷酸-L-丝氨酸(OPLS)以及脂质纳米盘相互作用的残基。最后,增加磷脂酰乙醇胺(PE)含量和减少 PS 含量会降低 FVIII 对膜表面的总体亲和力:本研究进一步揭示了 FVIII 如何与血小板相互作用形成固有十肽酶复合物的分子基础。
{"title":"Biophysical characterization of blood coagulation factor VIII binding to lipid nanodiscs that mimic activated platelet surfaces","authors":"Nathan G. Avery,&nbsp;Isabelle R. Young,&nbsp;Selena Lu,&nbsp;Jordan D. Vaughan,&nbsp;Patrick S. Korus,&nbsp;Tera N. Richardson,&nbsp;Kenneth C. Childers,&nbsp;Serge L. Smirnov,&nbsp;P. Clint Spiegel Jr.","doi":"10.1016/j.jtha.2024.11.003","DOIUrl":"10.1016/j.jtha.2024.11.003","url":null,"abstract":"<div><h3>Background</h3><div>Following proteolytic activation, activated blood coagulation factor (F)VIII (FVIIIa) binds to activated platelet membranes, forming the intrinsic tenase complex with activated FIX (FIXa). Previous studies have identified the C1 and C2 domains as the membrane binding domains of FVIII through conserved arginine residues. A membrane binding model for the FVIII C domains proposes that surface-exposed hydrophobic and positively charged residues at each C domain interact with the membrane, yet a comprehensive thermodynamic and structural description of this interaction is lacking.</div></div><div><h3>Objectives</h3><div>To determine residues of interaction, thermodynamics, and membrane binding preference for FVIII membrane association.</div></div><div><h3>Methods</h3><div>The binding of FVIII constructs to lipid nanodiscs was characterized by nuclear magnetic resonance, isothermal titration calorimetry, bio-layer interferometry, and X-ray crystallography.</div></div><div><h3>Results</h3><div>The thermodynamics of FVIII membrane binding indicated that the C1 domain associates through an enthalpically driven process while the C2 domain is entropically driven. Alanine mutations to surface-exposed hydrophobic residues in the C2 domain revealed differential effects on membrane binding, highlighting important determinants at the residue level. The structure of a C2 double mutant, L2251A/L2252A, demonstrated that its decreased affinity is likely due to decreasing the surface area hydrophobicity. Nuclear magnetic resonance studies with the C2 domain identified residues of interaction with soluble O-phospho-L-serine as well as lipid nanodiscs. Lastly, increasing phosphatidylethanolamine and decreasing phosphatidylserine content decreased overall FVIII affinity for membrane surfaces.</div></div><div><h3>Conclusion</h3><div>This study provides further insight into the molecular basis for how FVIII interacts with platelets to form the intrinsic tenase complex.</div></div>","PeriodicalId":17326,"journal":{"name":"Journal of Thrombosis and Haemostasis","volume":"23 2","pages":"Pages 513-524"},"PeriodicalIF":5.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142644048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Thrombotic complications in pregnancy: a case-based review of the evidence 妊娠期血栓并发症:基于病例的证据回顾。
IF 5.5 2区 医学 Q1 HEMATOLOGY Pub Date : 2025-02-01 DOI: 10.1016/j.jtha.2024.09.029
Lauren E. Merz MD , Bibi Bassa , Fionnuala Ní Áinle , Annemarie E. Fogerty
Pregnancy is a prothrombotic state due to an estrogen-driven shift in the coagulation system, increased venous stasis, and external restriction of blood flow caused by the gravid uterus. Venous thromboembolism (VTE) is a leading cause of morbidity and mortality in pregnancy. Preventing, recognizing, and treating thrombosis in pregnancy, as well as the postpartum period, often challenges decision making in the clinical setting. In early pregnancy, guidance with respects to thrombophilia testing and anticoagulation in increasing the likelihood of live birth among patients with recurrent miscarriages is evolving. This review explores emerging data that support clinical decision making in thrombosis care in women with common thrombotic complications in pregnancy. The first case outlines VTE diagnosis in pregnancy, initial anticoagulation management, management around delivery and postpartum, and subsequent long-term anticoagulation treatment. The second case examines testing for inherited and acquired thrombophilia in the setting of recurrent miscarriage and the management of obstetric antiphospholipid syndrome. Lastly, the third case reviews VTE risk assessment and prevention in pregnancy and the postpartum period, as well as duration and dose of postpartum thromboprophylaxis. Review of these common clinical scenarios surrounding thrombotic complications in pregnancy demonstrates recent advances in high-quality data, current gaps in knowledge, and variation in expert opinion. Ultimately, multidisciplinary discussion and teamwork remain key to optimal, safe care. Clinicians must prioritize collaborative, high-quality trials and prospective clinical management studies to better understand and define best practice in this population.
由于雌激素导致凝血系统发生变化、静脉淤血增加以及妊娠子宫对血流的外部限制,妊娠是一种促血栓形成状态。静脉血栓栓塞症(VTE)是妊娠期发病和死亡的主要原因。如何预防、识别和治疗妊娠期和产后血栓,往往是临床决策的难题。在妊娠早期,有关血栓性疾病检测和抗凝治疗以提高复发性流产患者活产几率的指导意见正在不断发展。本综述探讨了支持妊娠期常见血栓并发症妇女血栓护理临床决策的新兴数据。第一个病例概述了妊娠期 VTE 诊断、初始抗凝管理、分娩前后和产后管理以及随后的长期抗凝治疗。第二个病例探讨了复发性流产情况下的遗传性和获得性血栓性疾病检测,以及产科抗磷脂综合征的管理。最后,病例三回顾了孕期和产后的 VTE 风险评估和预防,以及产后血栓预防的持续时间和剂量。通过回顾这些常见的妊娠期血栓并发症临床案例,我们可以看到高质量数据的最新进展、当前的知识缺口以及专家意见的差异。最终,多学科讨论和团队合作仍是实现最佳安全护理的关键。临床医生必须优先考虑合作性、高质量的试验和前瞻性临床管理研究,以更好地了解和确定这一人群的最佳治疗方法。
{"title":"Thrombotic complications in pregnancy: a case-based review of the evidence","authors":"Lauren E. Merz MD ,&nbsp;Bibi Bassa ,&nbsp;Fionnuala Ní Áinle ,&nbsp;Annemarie E. Fogerty","doi":"10.1016/j.jtha.2024.09.029","DOIUrl":"10.1016/j.jtha.2024.09.029","url":null,"abstract":"<div><div>Pregnancy is a prothrombotic state due to an estrogen-driven shift in the coagulation system, increased venous stasis, and external restriction of blood flow caused by the gravid uterus. Venous thromboembolism (VTE) is a leading cause of morbidity and mortality in pregnancy. Preventing, recognizing, and treating thrombosis in pregnancy, as well as the postpartum period, often challenges decision making in the clinical setting. In early pregnancy, guidance with respects to thrombophilia testing and anticoagulation in increasing the likelihood of live birth among patients with recurrent miscarriages is evolving. This review explores emerging data that support clinical decision making in thrombosis care in women with common thrombotic complications in pregnancy. The first case outlines VTE diagnosis in pregnancy, initial anticoagulation management, management around delivery and postpartum, and subsequent long-term anticoagulation treatment. The second case examines testing for inherited and acquired thrombophilia in the setting of recurrent miscarriage and the management of obstetric antiphospholipid syndrome. Lastly, the third case reviews VTE risk assessment and prevention in pregnancy and the postpartum period, as well as duration and dose of postpartum thromboprophylaxis. Review of these common clinical scenarios surrounding thrombotic complications in pregnancy demonstrates recent advances in high-quality data, current gaps in knowledge, and variation in expert opinion. Ultimately, multidisciplinary discussion and teamwork remain key to optimal, safe care. Clinicians must prioritize collaborative, high-quality trials and prospective clinical management studies to better understand and define best practice in this population.</div></div>","PeriodicalId":17326,"journal":{"name":"Journal of Thrombosis and Haemostasis","volume":"23 2","pages":"Pages 417-428"},"PeriodicalIF":5.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142468679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Examining downstream effects of concizumab in hemophilia A with a mathematical modeling approach 用数学建模方法研究康舒单抗对血友病 A 的下游影响。
IF 5.5 2区 医学 Q1 HEMATOLOGY Pub Date : 2025-02-01 DOI: 10.1016/j.jtha.2024.10.028
Kenji Miyazawa , Alan E. Mast , Adam R. Wufsus , Michael Dockal , Marianne Kjalke , Karin Leiderman

Background

Tissue factor (TF) pathway inhibitor (TFPI) is an anticoagulant protein that inhibits factor (F)Xa, the TF-FVIIa-FXa complex, and early forms of the prothrombinase complex. Concizumab is a monoclonal antibody that blocks FXa inhibition by TFPI and reduces bleeding in hemophilia.

Objectives

To examine how concizumab impacts various reactions of TFPI to restore thrombin generation in hemophilia A using mathematical models.

Methods

A compartment model was used to estimate plasma concentrations of free concizumab and its complexes with TFPIα and TFPIβ. Concizumab was integrated into a flow-mediated mathematical model of coagulation, and a small injury was simulated under hemophilia A conditions. Simulations were then analyzed to determine how concizumab’s blockade of TFPI anticoagulant activities, specifically the inhibition of FXa in plasma and on platelets, inhibition of TF:FVIIa at the subendothelium, and prior sequestration of plasma TFPIα to the endothelium via TFPIβ, altered thrombin generation.

Results

Concizumab improved simulated thrombin generation in hemophilia A by simultaneously altering all 3 mechanisms of the TFPI anticoagulant blockade examined. Concizumab sequestered ∼75% of plasma TFPIα through the formation of ternary TFPIα-concizumab-TFPIβ-complexes. For all TF levels, reducing the TFPIα plasma concentration had the largest impact on the lag time, followed by blocking TFPIα inhibition of TF:FVIIa:FXa and subsequently by blocking TFPIα inhibition of FXa in plasma and on the platelet surface.

Conclusion

The effectiveness of concizumab is mediated through the blockade of TFPI anticoagulant activities in plasma and on multiple physiological surfaces. An important and previously unrecognized function of concizumab was the sequestration of plasma TFPIα to the endothelium.
背景:组织因子途径抑制剂(TFPI)是一种抗凝血蛋白,可抑制FXa、TF-FVIIa-FXa复合物以及凝血酶原酶复合物的早期形式。康妥珠单抗是一种单克隆抗体,可阻断 TFPI 对 FXa 的抑制,减少血友病患者的出血:利用数学模型研究康妥珠单抗如何影响 TFPI 的各种反应以恢复血友病 A 的凝血酶生成:方法:采用分区模型估算游离康珠单抗及其与 TFPIα 和 TFPIβ 复合物的血浆浓度。在血友病 A 的条件下,将康珠单抗整合到一个流动介导的凝血数学模型中,并模拟了一个小的损伤。然后对模拟结果进行分析,以确定康利珠单抗如何阻断 TFPI 抗凝活性,特别是如何抑制血浆中和血小板上的 FXa、抑制内皮下的 TF:VIIa 以及血浆 TFPIα 通过 TFPIβ 事先螯合到内皮,从而改变凝血酶的生成:结果:Concizumab通过同时改变TFPI抗凝阻断的三种机制,改善了血友病A的模拟凝血酶生成。通过形成三元 TFPIα-concizumab-TFPIβ 复合物,康舒单抗能封存血浆中 75% 的 TFPIα。在所有TF水平中,降低TFPIα血浆浓度对滞后时间的影响最大,其次是阻断TFPIα对TF:VIIa:FXa的抑制,随后是阻断TFPIα对血浆中和血小板表面FXa的抑制:结论:康居单抗的有效性是通过阻断血浆中和多个生理表面上的TFPI抗凝活性来实现的。康利珠单抗的一个以前未被认识到的重要功能是将血浆中的 TFPIα 封闭在血管内皮中。
{"title":"Examining downstream effects of concizumab in hemophilia A with a mathematical modeling approach","authors":"Kenji Miyazawa ,&nbsp;Alan E. Mast ,&nbsp;Adam R. Wufsus ,&nbsp;Michael Dockal ,&nbsp;Marianne Kjalke ,&nbsp;Karin Leiderman","doi":"10.1016/j.jtha.2024.10.028","DOIUrl":"10.1016/j.jtha.2024.10.028","url":null,"abstract":"<div><h3>Background</h3><div>Tissue factor (TF) pathway inhibitor (TFPI) is an anticoagulant protein that inhibits factor (F)Xa, the TF-FVIIa-FXa complex, and early forms of the prothrombinase complex. Concizumab is a monoclonal antibody that blocks FXa inhibition by TFPI and reduces bleeding in hemophilia.</div></div><div><h3>Objectives</h3><div>To examine how concizumab impacts various reactions of TFPI to restore thrombin generation in hemophilia A using mathematical models.</div></div><div><h3>Methods</h3><div>A compartment model was used to estimate plasma concentrations of free concizumab and its complexes with TFPIα and TFPIβ. Concizumab was integrated into a flow-mediated mathematical model of coagulation, and a small injury was simulated under hemophilia A conditions. Simulations were then analyzed to determine how concizumab’s blockade of TFPI anticoagulant activities, specifically the inhibition of FXa in plasma and on platelets, inhibition of TF:FVIIa at the subendothelium, and prior sequestration of plasma TFPIα to the endothelium via TFPIβ, altered thrombin generation.</div></div><div><h3>Results</h3><div>Concizumab improved simulated thrombin generation in hemophilia A by simultaneously altering all 3 mechanisms of the TFPI anticoagulant blockade examined. Concizumab sequestered ∼75% of plasma TFPIα through the formation of ternary TFPIα-concizumab-TFPIβ-complexes. For all TF levels, reducing the TFPIα plasma concentration had the largest impact on the lag time, followed by blocking TFPIα inhibition of TF:FVIIa:FXa and subsequently by blocking TFPIα inhibition of FXa in plasma and on the platelet surface.</div></div><div><h3>Conclusion</h3><div>The effectiveness of concizumab is mediated through the blockade of TFPI anticoagulant activities in plasma and on multiple physiological surfaces. An important and previously unrecognized function of concizumab was the sequestration of plasma TFPIα to the endothelium.</div></div>","PeriodicalId":17326,"journal":{"name":"Journal of Thrombosis and Haemostasis","volume":"23 2","pages":"Pages 480-491"},"PeriodicalIF":5.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142622735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hemostatic derangements associated with cardiopulmonary bypass predict outcomes in pediatric patients undergoing corrective heart surgery 与心肺旁路相关的止血失调可预测接受心脏矫正手术的儿科患者的预后。
IF 5.5 2区 医学 Q1 HEMATOLOGY Pub Date : 2025-02-01 DOI: 10.1016/j.jtha.2024.10.029
Kevin Todd , Spencer J. Hogue , James S. Tweddell , James A. Reagor , Eric Mullins , Mary G. Block , Leah Rosenfeldt , Brenton Francisco , Sonata Jodele , Bal Krishan Sharma , Adam Lane , Craig Slusher , Mousa Kharnaf , David L.S. Morales , Joseph S. Palumbo

Background

Understanding of the hemostatic and complement alterations associated with cardiopulmonary bypass (CPB) in pediatric patients and the impact of these alterations on outcome is limited.

Objectives

The present study prospectively characterized these alterations and their association with postoperative outcomes in pediatric CPB.

Methods

All patients aged <21 years undergoing CPB at the authors’ institution between 2020 and 2021 who weighed >3 kg, were >36 weeks gestational age, and had no known prothrombotic or hemorrhagic disorders were eligible. Blood samples were analyzed for multiple hemostatic and complement biomarkers pre-, intra-, and 24 hours post-CPB. Biomarker levels were compared to clinical outcomes, including chest tube output (CTO).

Results

Fifty consecutive patients were enrolled. CPB resulted in multiple significant alterations in hemostatic and complement components. Lower platelet counts (<80 × 109 platelets/L) at CPB termination were associated with increased postoperative CTO (P = .003). Lower factor (F)VIII levels (<60 IU/dL) at the end of CPB were associated with a longer hospital stay (P < .001) and increased postoperative CTO (P < .001). Patients undergoing staged single ventricle reconstruction were more likely to have lower platelet counts at CPB termination (P = .009) and higher CTO postoperatively (P = .001) than patients undergoing other types of surgical repair. These differences were not due to different preoperative platelet counts, increased incidences of circulatory arrest, or longer CPB times.

Conclusion

These data suggest that intraoperative alterations in hemostatic system components may predict postoperative outcomes in pediatric CPB. Further study is needed to determine if interventions targeting platelets or FVIII could improve outcomes in pediatric CPB.
背景:对儿科患者心肺旁路(CPB)相关的止血和补体改变以及这些改变对预后的影响了解有限:本研究对这些改变及其与小儿 CPB 术后结果的关系进行了前瞻性描述:所有体重 3 公斤、胎龄大于 36 周、无已知血栓或出血性疾病的患者均符合条件。在心肺复苏术前、术中和术后 24 小时对血液样本进行多种止血和补体生物标志物分析。将生物标志物水平与临床结果(包括胸导管输出量(CTO))进行比较:结果:50 名患者连续接受了 CPB。心肺复苏术导致止血和补体成分发生多种明显变化。CPB 终止时较低的血小板计数(9 个血小板/L)与术后 CTO 增加有关(p=0.003)。因子 VIII 水平较低(结论:这些数据表明,术中止血系统成分的改变可预测小儿 CPB 的术后结果。需要进一步研究以确定针对血小板或因子 VIII 的干预措施是否能改善小儿 CPB 的预后。
{"title":"Hemostatic derangements associated with cardiopulmonary bypass predict outcomes in pediatric patients undergoing corrective heart surgery","authors":"Kevin Todd ,&nbsp;Spencer J. Hogue ,&nbsp;James S. Tweddell ,&nbsp;James A. Reagor ,&nbsp;Eric Mullins ,&nbsp;Mary G. Block ,&nbsp;Leah Rosenfeldt ,&nbsp;Brenton Francisco ,&nbsp;Sonata Jodele ,&nbsp;Bal Krishan Sharma ,&nbsp;Adam Lane ,&nbsp;Craig Slusher ,&nbsp;Mousa Kharnaf ,&nbsp;David L.S. Morales ,&nbsp;Joseph S. Palumbo","doi":"10.1016/j.jtha.2024.10.029","DOIUrl":"10.1016/j.jtha.2024.10.029","url":null,"abstract":"<div><h3>Background</h3><div>Understanding of the hemostatic and complement alterations associated with cardiopulmonary bypass (CPB) in pediatric patients and the impact of these alterations on outcome is limited.</div></div><div><h3>Objectives</h3><div>The present study prospectively characterized these alterations and their association with postoperative outcomes in pediatric CPB.</div></div><div><h3>Methods</h3><div>All patients aged &lt;21 years undergoing CPB at the authors’ institution between 2020 and 2021 who weighed &gt;3 kg, were &gt;36 weeks gestational age, and had no known prothrombotic or hemorrhagic disorders were eligible. Blood samples were analyzed for multiple hemostatic and complement biomarkers pre-, intra-, and 24 hours post-CPB. Biomarker levels were compared to clinical outcomes, including chest tube output (CTO).</div></div><div><h3>Results</h3><div>Fifty consecutive patients were enrolled. CPB resulted in multiple significant alterations in hemostatic and complement components. Lower platelet counts (&lt;80 × 10<sup>9</sup> platelets/L) at CPB termination were associated with increased postoperative CTO (<em>P</em> = .003). Lower factor (F)VIII levels (&lt;60 IU/dL) at the end of CPB were associated with a longer hospital stay (<em>P</em> &lt; .001) and increased postoperative CTO (<em>P</em> &lt; .001). Patients undergoing staged single ventricle reconstruction were more likely to have lower platelet counts at CPB termination (<em>P</em> = .009) and higher CTO postoperatively (<em>P</em> = .001) than patients undergoing other types of surgical repair. These differences were not due to different preoperative platelet counts, increased incidences of circulatory arrest, or longer CPB times.</div></div><div><h3>Conclusion</h3><div>These data suggest that intraoperative alterations in hemostatic system components may predict postoperative outcomes in pediatric CPB. Further study is needed to determine if interventions targeting platelets or FVIII could improve outcomes in pediatric CPB.</div></div>","PeriodicalId":17326,"journal":{"name":"Journal of Thrombosis and Haemostasis","volume":"23 2","pages":"Pages 492-503"},"PeriodicalIF":5.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142622771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corrigendum to ‘Extending Venous Thromboembolism Secondary Prevention with Apixaban in Cancer Patients. The EVE Trial’ 阿哌沙班在癌症患者中扩展静脉血栓栓塞二级预防的勘误。EVE试验:[Journal of Thrombosis and heemostasis Volume 22, Issue 6, June 2024, Pages 1704-1714]。
IF 5.5 2区 医学 Q1 HEMATOLOGY Pub Date : 2025-02-01 DOI: 10.1016/j.jtha.2024.12.011
Robert D. McBane II , Charles L. Loprinzi , Tyler Zemla , Alfonso Tafur , Kristen Sanfilippo , Jane Jijun Liu , David A. Garcia , James Heun , Krishna Gundabolu , Adedayo A. Onitilo , Usha Perepu , Monic R. Drescher , Stanislav Henkin , Damon Houghton , Aneel Ashrani , Henny Billett , Micah J. Mooberry , Shaylene A. McCue , Minji K. Lee , Jennifer G. Le-Rademacher , Waldemar E. Wysokinski
{"title":"Corrigendum to ‘Extending Venous Thromboembolism Secondary Prevention with Apixaban in Cancer Patients. The EVE Trial’","authors":"Robert D. McBane II ,&nbsp;Charles L. Loprinzi ,&nbsp;Tyler Zemla ,&nbsp;Alfonso Tafur ,&nbsp;Kristen Sanfilippo ,&nbsp;Jane Jijun Liu ,&nbsp;David A. Garcia ,&nbsp;James Heun ,&nbsp;Krishna Gundabolu ,&nbsp;Adedayo A. Onitilo ,&nbsp;Usha Perepu ,&nbsp;Monic R. Drescher ,&nbsp;Stanislav Henkin ,&nbsp;Damon Houghton ,&nbsp;Aneel Ashrani ,&nbsp;Henny Billett ,&nbsp;Micah J. Mooberry ,&nbsp;Shaylene A. McCue ,&nbsp;Minji K. Lee ,&nbsp;Jennifer G. Le-Rademacher ,&nbsp;Waldemar E. Wysokinski","doi":"10.1016/j.jtha.2024.12.011","DOIUrl":"10.1016/j.jtha.2024.12.011","url":null,"abstract":"","PeriodicalId":17326,"journal":{"name":"Journal of Thrombosis and Haemostasis","volume":"23 2","pages":"Page 756"},"PeriodicalIF":5.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142872468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Annoucements
IF 5.5 2区 医学 Q1 HEMATOLOGY Pub Date : 2025-02-01 DOI: 10.1016/S1538-7836(25)00041-8
{"title":"Annoucements","authors":"","doi":"10.1016/S1538-7836(25)00041-8","DOIUrl":"10.1016/S1538-7836(25)00041-8","url":null,"abstract":"","PeriodicalId":17326,"journal":{"name":"Journal of Thrombosis and Haemostasis","volume":"23 2","pages":"Page 757"},"PeriodicalIF":5.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143179417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pazopanib in treatment of hereditary hemorrhagic telangiectasia-related epistaxis and gastrointestinal bleeding 帕唑帕尼(Pazopanib)用于治疗遗传性出血性远端血管扩张症相关的鼻衄和消化道出血。
IF 5.5 2区 医学 Q1 HEMATOLOGY Pub Date : 2025-02-01 DOI: 10.1016/j.jtha.2024.10.014
Magdalena D. Lewandowska, Shelby Gordon, Anthony Betbadal, Amy D. Shapiro

Background

Hereditary hemorrhagic telangiectasia (HHT) is a bleeding disorder characterized by arteriovenous malformations, commonly presenting with epistaxis and gastrointestinal (GI) bleeding. Bleeding symptoms may be difficult to manage and may become life-threatening, with many patients developing dependence on parenteral iron and/or blood transfusion. There is a growing body of evidence that antiangiogenic therapies may be effective in management of bleeding symptoms, presumably targeting pathogenic HHT pathways such as vascular endothelial growth factor receptor.

Objectives

To report single-center, retrospective real-world use of pazopanib, an orally administered tyrosine kinase inhibitor that blocks vascular endothelial growth factor receptors, in 6 patients with HHT-associated epistaxis and/or GI bleeding.

Methods

A retrospective observational analysis was performed to assess the safety/efficacy of pazopanib use in patients with confirmed HHT-associated epistaxis and/or GI bleeding between January 1, 2019, and June 14, 2023. The Indiana Hemophilia and Thrombosis institutional electronic medical record was queried for HHT patients who were treated with pazopanib for ≥3 months. Patient data were obtained from patient documentation, physician/nursing notes, and on-call documentation. Institutional review board approval was obtained for data pull as an exempt study.

Results

Our observations on the real-world use of pazopanib in 6 HHT patients with moderate-to-severe bleeding showed improvement in hemoglobin levels, with reduction in iron infusions and red blood cell transfusion requirement.

Conclusion

Pazopanib may be a reasonable option for patients with HHT with epistaxis or gastrointestinal bleeding that are refractory to standard treatment.
背景:遗传性出血性毛细血管扩张症(HHT)是一种以动静脉畸形(AVM)为特征的出血性疾病,通常表现为鼻衄和消化道出血。出血症状可能难以控制,并可能危及生命,许多患者开始依赖肠外铁剂和/或输血。越来越多的证据表明,抗血管生成疗法可有效控制出血症状,可能是针对血管内皮生长因子(VEGF)受体等 HHT 致病途径:报告帕唑帕尼(一种阻断血管内皮生长因子受体的口服酪氨酸激酶抑制剂)在6例HHT相关性鼻衄和/或胃肠道(GI)出血患者中的单中心、回顾性实际应用情况:对2019年1月1日至2023年6月14日期间确诊的HHT相关性鼻衄和/或消化道出血患者使用帕唑帕尼的安全性/有效性进行了回顾性观察分析,并查询了印第安纳州血友病和血栓症(IHTC)机构的EMR,以了解接受帕唑帕尼治疗超过3个月的HHT患者的情况。患者数据来自患者文档、医生/护理记录和值班文档。作为一项豁免研究,数据拉取已获得机构 IRB 批准。 结果与结论:我们观察到帕唑帕尼在现实世界中的使用情况:我们对 6 名中重度出血的 HHT 患者实际使用帕唑帕尼的观察结果显示,血红蛋白水平有所改善,铁剂输注和红细胞输注需求减少。对于标准治疗难治的鼻衄或消化道出血 HHT 患者,帕唑帕尼可能是一个合理的选择。
{"title":"Pazopanib in treatment of hereditary hemorrhagic telangiectasia-related epistaxis and gastrointestinal bleeding","authors":"Magdalena D. Lewandowska,&nbsp;Shelby Gordon,&nbsp;Anthony Betbadal,&nbsp;Amy D. Shapiro","doi":"10.1016/j.jtha.2024.10.014","DOIUrl":"10.1016/j.jtha.2024.10.014","url":null,"abstract":"<div><h3>Background</h3><div>Hereditary hemorrhagic telangiectasia (HHT) is a bleeding disorder characterized by arteriovenous malformations, commonly presenting with epistaxis and gastrointestinal (GI) bleeding. Bleeding symptoms may be difficult to manage and may become life-threatening, with many patients developing dependence on parenteral iron and/or blood transfusion. There is a growing body of evidence that antiangiogenic therapies may be effective in management of bleeding symptoms, presumably targeting pathogenic HHT pathways such as vascular endothelial growth factor receptor.</div></div><div><h3>Objectives</h3><div>To report single-center, retrospective real-world use of pazopanib, an orally administered tyrosine kinase inhibitor that blocks vascular endothelial growth factor receptors, in 6 patients with HHT-associated epistaxis and/or GI bleeding.</div></div><div><h3>Methods</h3><div>A retrospective observational analysis was performed to assess the safety/efficacy of pazopanib use in patients with confirmed HHT-associated epistaxis and/or GI bleeding between January 1, 2019, and June 14, 2023. The Indiana Hemophilia and Thrombosis institutional electronic medical record was queried for HHT patients who were treated with pazopanib for ≥3 months. Patient data were obtained from patient documentation, physician/nursing notes, and on-call documentation. Institutional review board approval was obtained for data pull as an exempt study.</div></div><div><h3>Results</h3><div>Our observations on the real-world use of pazopanib in 6 HHT patients with moderate-to-severe bleeding showed improvement in hemoglobin levels, with reduction in iron infusions and red blood cell transfusion requirement.</div></div><div><h3>Conclusion</h3><div>Pazopanib may be a reasonable option for patients with HHT with epistaxis or gastrointestinal bleeding that are refractory to standard treatment.</div></div>","PeriodicalId":17326,"journal":{"name":"Journal of Thrombosis and Haemostasis","volume":"23 2","pages":"Pages 525-530"},"PeriodicalIF":5.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142502859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Thrombosis and Haemostasis
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1